The relationship between single nucleotide polymorphisms in 5-HT2A signal transduction-related genes and the response efficacy to selective serotonin reuptake inhibitor treatments in Chinese patients with major depressive disorder

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 7, 2012, Pages 667-671

  Li, Heng Fen ^a   Yu, Xue ^b,c   Yang, Kun ^b,c   He, Cha Ye ^d   Kou, Shao Jie ^e   Cao, Su Xia ^a   Xie, Guang Rong ^f  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c TIANJIN ANDING HOSPITAL   (China)

^d HENAN INSTITUTE OF SCIENCE AND TECHNOLOGY   (China)

^e Department of Psychiatry   (China)

^f CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACDY9 PROTEIN; BIOLOGICAL MARKER; CITALOPRAM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; G BETA 3 PROTEIN; PAROXETINE; PDE1A PROTEIN; SEROTONIN 2A RECEPTOR; SERTRALINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHINESE; DRUG EFFICACY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OPEN STUDY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT2A; SECOND MESSENGER SYSTEMS; SEROTONIN UPTAKE INHIBITORS;

EID: 84863901140     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0232     Document Type: Article

References (23)

1. Blier P (2001) Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 62 Suppl 15:12-17. (Pubitemid 32601343)
2. Chen A-H, Shirayama Y, Shin K-H, et al. (2001) Expression of the cAMP response element binding protein (CREB) in hippocampus produces antidepressant effect. Biol Psychiatry 49: 753-762. (Pubitemid 32452296)
3. Chen Z, Skolnick P (2007) Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs 16:1365-1377. (Pubitemid 47491407)
4. Cheng Z, Sheldrick EL, Marshall E, et al. (2007) Control of cyclic AMP concentration in bovine endometrial stromal cells by arachidonic acid. Reproduction 133:1017-1026. (Pubitemid 47162591)
5. Crossley NA, Bauer M (2007) Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 68:935-940. (Pubitemid 47015495)
6. Demyttenaere K, Bonnewyn A, Bruffaerts R, et al. (2008) Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD). J Affect Disord 110:84-93.
7. Girigoswami A, Jung C, Mun HY, Park HG (2008) PCR-free mutation detection of BRCA1 on a zip-code microarray using ligase chain reaction. J Biochem Biophys Methods 70:897-902.
8. Gould TD, Manji HK (2002) Signaling networks in the patho-physiology and treatment of mood disorders. Psychosom Res 53:687-697. (Pubitemid 36292448)
9. Gros R, Ding Q, Cao H, et al. (2005) Feldman RD identification of a dysfunctional missense single nucleotide variant of human adenylyl cyclase VI. Clin Pharmacol Ther 77:271-278. (Pubitemid 40470383)
10. Guzzetta F, Tondo L, Centorrino F, et al. (2007) Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 68:380-383. (Pubitemid 46506801)
11. Hines LM, Hoffman PL, Bhave S, et al. (2006) A sex-specific role of type VII adenylyl cyclase in depression. J Neurosci 26: 12609-12619. (Pubitemid 44864526)
12. Hines LM, Tabakoff B (2005) WHO/ISBR A study on state and trait markers of alcohol use and dependence investigators platelet adenylyl cyclase activity: a biological marker for major depression and recent drug use. Biol Psychiatry 58:955-962. (Pubitemid 41790705)
13. Iwatsubo K, Okumura S, Ishikawa Y (2006) Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling. Endocr Metab Immune Disord Drug Targets 6:239-247. (Pubitemid 44383207)
14. Lee HJ, Cha JH, Ham BJ, et al. (2004) Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J 4:29-33.
15. Levinson DF (2006) The genetics of depression: a review. Biol Psychiatry 60:84-92.
16. Lin E, Chen PS, Chang HH, Gean PW, Tsai HC, Yang YK, Lu RB (2009) Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 33:1167-1172.
17. Lohoff FW (2010) Overview of the genetics of major depressive disorder. Curr Psychiatry Rep 12:539-546.
18. Mato S, Vidal R, Castro E, D́iaz A, Pazos A, Valdizán EM (2010) Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine 1A receptor-dependent mechanisms. Mol Pharmacol 77:424-434.
19. McMahon FJ, Buervenich S, Chamey D, Lipsky R, Rush AJ, Wilson AF, et al. (2006) Variation in the gene enconding the serotonin 2A receptor is associated with outcome of antide-pressant treatment. Am J Hum Genet 78:804-814.
20. Neumeister A (2003) Tryptophan depletion, serotonin, and depression: where do we stand? Psychopharmacol Bull 37: 99-115.
21. Sullivan PF, Neale MC, Kendler KS (2000) Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 157:1552-1562.
22. Wender PH, Kety SS, Rosenthal D, et al. (1986) Psychiatric disorders in the biological and adoptive families of adopted individuals with affective disorders. Arch Gen Psychiatry 43:923-929. (Pubitemid 17168411)
23. Wilkie MJ, Smith D, Reid IC, et al. (2007) A splice site polymorphism in the G-protein beta subunit influences antide-pressant efficacy in depression. Pharmacogenet Genomics 17: 207-215. (Pubitemid 46668005)